

Supplementary Files

Supplementary Table S1 Positive rate of plasma mSEPT9 in each enrolled group using 1/3 algorithm.

Characteristics	N	mSEPT9	
		N	%
CRC	98	79	80.6
0	3	1	33.3
I	23	16	69.6
II	31	24	77.4
III	31	29	93.5
IV	8	8	100.0
Unknown	2	1	50.0
Adenomas	101	17	16.8
Non-colorectal Cancer	76	29	38.2
Gastric cancer	10	8	80.0
Breast cancer	58	20	34.5
Other cancer	8	1	12.5
Inflammation	30	7	23.3
Gastroenteritis	26	6	23.1
Other Inflammation	4	1	25.0
NED	253	35	13.8

CRC, colorectal cancer; NED, no evidence of diseases; [†], compared with NED (Ref.); [‡], compared with CRC (Ref.).

Supplementary Table S2 Diagnostic test evaluation of plasma mSEPT9 for CRC using 1/3 algorithm.

	mSEPT9 [†]	mSEPT9 [‡]
Sensitivity (95% CI)	80.61% (71.69% - 87.22%)	80.61% (71.69% - 87.22%)
Specificity (95% CI)	86.17% (81.37% - 89.88%)	80.87% (77.03% - 84.20%)
PPV (95% CI)	69.30% (60.32% - 77.02%)	47.31% (39.88% - 54.85%)
NPV (95% CI)	91.98% (87.82% - 94.81%)	95.14% (92.54% - 96.87%)

PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval; [†], mSEPT9 in subjects with colorectal cancer versus no evidence of diseases; [‡], mSEPT9 in subjects with colorectal cancer versus all the other enrolled subjects including adenoma, non-colorectal cancer, inflammation, and no evidence of disease samples.